Efficacy and Tolerability of Anti-CGRP Monoclonal Antibodies in Patients Aged ≥ 65 Years With Daily or Nondaily Migraine
This retrospective analysis provides real-world evidence that there is no difference in the efficacy and tolerability of treatment with erenumab, fremanezumab, and galcanezumab in patients O65 when compared with patients U65 both with daily or nondaily migraine. These data may help guide the choice of migraine treatment in older populations.
Authors
- Elise Hennessy (ORCID: https://orcid.org/0000-0003-2128-632X)
- Olivia Hogue (ORCID: https://orcid.org/0000-0002-3985-3831)
- MaryAnn Mays (ORCID: https://orcid.org/0000-0002-6957-4219)
- Zubair Ahmed (ORCID: https://orcid.org/0000-0002-7580-7453)
- Amira Salim (ORCID: https://orcid.org/0000-0001-5300-3983)
- Ignacio Fernandez Mata (ORCID: https://orcid.org/0000-0003-1198-0633)
- Claire Sonneborn (ORCID: https://orcid.org/0000-0003-3038-5418)
- Aarushi Suneja
- Sudipa Biswas
Institutions
- Cleveland Clinic Lerner College of Medicine (US)
Publication Details
- Journal
- Neurology Clinical Practice
- Published
- 2024-10-08
- DOI
- https://doi.org/10.1212/cpj.0000000000200373
- Citations
- 3
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.16